- Home
- VRDN vs GRDN Comparison
VRDN vs GRDN Comparison
Compare VRDN & GRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- GRDN
- Stock Information
- Founded
- VRDN 2006
- GRDN 2004
- Country
- VRDN United States
- GRDN United States
- Employees
- VRDN N/A
- GRDN N/A
- Industry
- VRDN Medical Specialities
- GRDN Retail-Drug Stores and Proprietary Stores
- Sector
- VRDN Health Care
- GRDN Consumer Staples
- Exchange
- VRDN Nasdaq
- GRDN Nasdaq
- Market Cap
- VRDN 1.5B
- GRDN 1.8B
- IPO Year
- VRDN N/A
- GRDN 2024
- Fundamental
- Price
- VRDN $18.72
- GRDN $28.20
- Analyst Decision
- VRDN Strong Buy
- GRDN Strong Buy
- Analyst Count
- VRDN 11
- GRDN 2
- Target Price
- VRDN $38.80
- GRDN $24.50
- AVG Volume (30 Days)
- VRDN 894.1K
- GRDN 327.1K
- Earning Date
- VRDN 08-06-2025
- GRDN 08-11-2025
- Dividend Yield
- VRDN N/A
- GRDN N/A
- EPS Growth
- VRDN N/A
- GRDN N/A
- EPS
- VRDN N/A
- GRDN N/A
- Revenue
- VRDN $305,000.00
- GRDN $1,326,604,000.00
- Revenue This Year
- VRDN N/A
- GRDN $16.17
- Revenue Next Year
- VRDN $35,092.81
- GRDN $2.31
- P/E Ratio
- VRDN N/A
- GRDN N/A
- Revenue Growth
- VRDN 5.90
- GRDN 18.53
- 52 Week Low
- VRDN $9.90
- GRDN $14.16
- 52 Week High
- VRDN $27.20
- GRDN $28.80
- Technical
- Relative Strength Index (RSI)
- VRDN 55.80
- GRDN 76.41
- Support Level
- VRDN $18.12
- GRDN $25.09
- Resistance Level
- VRDN $20.05
- GRDN $26.80
- Average True Range (ATR)
- VRDN 1.02
- GRDN 1.09
- MACD
- VRDN -0.02
- GRDN 0.23
- Stochastic Oscillator
- VRDN 55.81
- GRDN 88.48
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).
About GRDN Guardian Pharmacy Services Inc. Class A Common Stock
Guardian Pharmacy Services Inc is a differentiated pharmacy services company that provides an extensive suite of technology-enabled services designed to help residents of LTCFs adhere to their appropriate drug regimen, which in turn helps reduce the cost of care and improve clinical outcomes. The company emphasizes high-touch, individualized clinical, drug dispensing, and administration capabilities that are tailored to serve the needs of residents in historically lower acuity LTCFs, such as ALFs and BHFs. The operating segment derives its revenues through sales of pharmaceutical and medical products, and all revenues are derived solely in the United States.